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Muscle mass and function are gradually lost in age-related, degenerative neuromuscular
disorders, which also reflect the clinical hallmarks of sarcopenia. The consensus defini-
tion of sarcopenia includes a condition of age-related loss of muscle mass, quality, and
strength. The most common acquired muscle disease affecting adults aged over 50 years
is sporadic inclusion body myositis (sIBM). Besides inflammatory effects and immune-
mediated muscle injury, degenerative myofiber changes are characteristic features of the
disease. Although the earliest triggering events in sIBM remain elusive, a plethora of down-
stream mechanisms are implicated in the pathophysiology of muscle wasting. Although it
remains controversial whether hereditary forms of inclusion body myopathy (IBM) may be
considered as degenerative sIBM disease models, partial pathophysiological aspects can
mimic the much more frequent sporadic condition, in particular the occurrence of inclusion
bodies in skeletal muscle. Various clinical aspects in genetically determined skeletal mus-
cle disorders reflect age-related alterations observed in sarcopenia. Several intriguing clues
from monogenic defects in heritable IBMs contributing to the molecular basis of muscle
loss will be discussed with special emphasis on inclusion body myopathy with Paget’s
disease of bone and frontotemporal dementia (IBMPFD) and GNE myopathy. Finally, also
the recently identified dominant multisystem proteinopathy will be considered, which may
rarely present as IBM.
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INTRODUCTION
Pathogenic mutations in genes involved in diverse cellular path-
ways as VCP/p97, also called valosin-containing protein [resulting
in autosomal-dominant inclusion body myopathy (IBM) asso-
ciated with Paget’s disease of bone and frontotemporal demen-
tia, IBMPFD] and GNE, also referred to as UDP-N -acetyl-d-
glucosamine 2-epimerase/N -acetylmannosamine kinase (GNE)
(resulting in biallelic GNE myopathy) can elicit a pathophys-
iological phenotype in skeletal muscle that partially overlaps
with histopathology findings in sporadic inclusion body myositis
(sIBM), in particular the detection of inclusion bodies in skeletal
muscle. While formal proof is lacking, it remains a hypothesis that
genetically determined IBM syndromes may share some aspects of
the pathogenetic cascade.
However, immune-mediated, inflammatory changes are a hall-
mark of sIBM and only a very rare exception in GNE myopathy
(Krause et al., 2003; Yabe et al., 2003). Furthermore, the typical
clinical presentation of sIBM features progressive muscle weakness
in the knee extensors and the long finger flexors (Rose and ENMC
IBM Working Group, 2013). By contrast, in GNE myopathy the
quadriceps muscles are remarkably spared from muscle weakness
(reviewed in Nishino et al., 2014). IBMPFD patients present clin-
ically with a variable pattern of slowly progressive proximal and
distal pareses (reviewed in Weihl et al., 2009). Scapular winging
in IBMPFD may be as prominent as in neuromuscular shoulder
girdle or limb girdle syndromes (Kimonis et al., 2008; Stojkovic
et al., 2009).
VCP/p97 acts as an ubiquitin-selective multitasking switch-
board in regulating basic cellular proteostasis including autophagy
and myosin assembly in skeletal muscle (reviewed by Pokrzywa
and Hoppe, 2013; Meyer and Weihl, 2014). GNE, the key enzyme
of sialic acid biosynthesis, can regulate muscle glycoprotein sialyla-
tion and might contribute to additional cellular signaling pathways
(reviewed by Nishino et al., 2014). HNRNPA1, the ubiquitously
expressed gene for the heterogeneous nuclear ribonucleoprotein
A1 is the causative gene for the rare multisystem proteinopathy,
which may be associated with IBM was identified only very recently
(Kim et al., 2013a).
In the adult-onset, heritable degenerative neuromuscular dis-
orders, muscle mass and function are gradually lost and reflect
the clinical hallmarks of sarcopenia. The consensus definition of
sarcopenia includes a condition of age-related loss of muscle mass,
quality, and strength (Cruz-Jentoft et al., 2010; Fielding et al.,
2011). Key findings potentially related to sarcopenia at multiple
levels of muscle metabolism in hereditary IBMs like IBMPFD and
GNE myopathy as well as the HNRNPA1-associated multisystem
proteinopathy presenting as IBM will be highlighted.
IBMPFD ASSOCIATED WITH VCP/p97 MUTATIONS
The multifaceted role of the AAA-family ATPase VCP/p97 in the
pathophysiology of IBMPFD involves numerous essential signal-
ing pathways governing cellular homeostasis and depends on the
cellular context. To exploit the therapeutic potential of VCP/p97,
it is important to understand how its activity is regulated and
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how specific organs and cells can be targeted to regulate the versa-
tile enzyme. The specificity of VCP/p97 depends significantly on
cofactors, which confer precise catalytic function. The majority
of pathogenic mutations in VCP/p97 resulting in neuromuscu-
lar disorders are localized in the cofactor binding domain (Tang
et al., 2010) and abrogate binding to a distinct subset of cofactors
(Fernandez-Saiz and Buchberger, 2010).
Myosin filament assembly is disturbed in myogenic cells from
IBMPFD patients in vitro (Janiesch et al., 2007). Functional devel-
opment of striated muscle depends on the accurate organization
of regulatory, structural, and motor proteins into basic contrac-
tile elements called the sarcomeres. VCP/p97 acts in a ternary
complex together with the cofactors CHIP and UFD2a to tightly
regulate the level of the myosin-directed chaperone Unc45 within
confined limits, which allow proper myosin filament assembly
and sarcomere formation (Janiesch et al., 2007). CHIP is also
called carboxyl terminus of Hsp70-interacting protein. UFD2a is
the human homolog of yeast UFD2a, also known as ubiquitina-
tion factor E4B (UBE4B) and human Unc45 is the homolog of
the C. elegans Unc45 chaperone, which is essential to regulate
myosin-directed functions from fungi to vertebrates (reviewed
in Hellerschmied and Clausen, 2014). Defective myosin assem-
bly may contribute to myofiber fragility and reduced mechanical
stability. Inclusion bodies might develop secondary and due high
amounts of accumulated, unassembled myosin in the sarcoplasm.
Similarly, in another form of familial IBM (IBM 3), dominantly
inherited mutations in the head domain of MYH2 (adult skeletal
muscle myosin heavy chain 2, fast myosin IIa) render MYH2 fil-
ament proteins to aggregate (Martinsson et al., 2000; Tajsharghi
et al., 2005). Deregulated, elevated levels of Unc45 in skeletal mus-
cle of affected IBMPFD patients suggest a related, relevant myosin
biosynthesis defect in vivo.
Furthermore, deregulation of major protein degradation path-
ways has been implicated in VCP/p97-related disorders (Ju et al.,
2009a,b; Tresse et al., 2010). An imbalance in protein turnover
contributes also to muscle loss in sarcopenia (Barns et al., 2014).
Primary human myoblasts containing disease-related VCP/p97
mutations revealed increased apoptosis and defective matura-
tion to myotubes in vitro (Vesa et al., 2009). This suggests that
IBMPFD satellite cells have a reduced regeneration capability,
and may generate defective myotubes thus contributing to muscle
degeneration.
Furthermore, VCP/p97 is essential for mitochondrial quality
control by PINK1/Parkin (PTEN induced putative kinase 1), which
is associated with autosomal-recessive early-onset Parkinson dis-
ease. PINK1 prevents stress-induced mitochondrial dysfunction.
This important protective capacity is impaired by disease-related
VCP/p97 mutations (Kim et al., 2013b). Mutant VCP/p97 mal-
function involves recruitment to and clearance of damaged mito-
chondria. These processes are paralleled in part by the mito-
chondrial theory of aging, which predicts the accumulation of
damage by reactive oxygen species (ROS) over time to lead to age-
associated mitochondrial impairment (Cesari et al., 2012; Johnson
et al., 2013).
Epigenetic changes have been implicated in sarcopenia; how-
ever, detailed evidence is limited (Ong and Holbrook, 2014). For
efficient gene expression, dynamic cycles of monoubiquitylation
and de-ubiquitylation are indispensable (Wyce et al., 2007). In
a collaborative project, we defined a novel regulatory role of
VCP/p97 in histone H2B metabolism, which is conserved from
yeast to man. Moreover, in IBMPFD cells carrying a point muta-
tion at the highly conserved residue R155H that does not affect the
ATPase activity, H2B de-ubiquitylation was significantly delayed
48 h after induction of differentiation in vitro. Our findings fur-
ther extend the functional spectrum of VCP/p97 and suggest an
additional molecular pathomechanism for IBMPFD at the level of
chromatin remodeling and transcription control (Bonizec et al.,
2015).
GNE MYOPATHY
GNE myopathy is an inherited autosomal-recessive IBM. The
causative gene was identified more than a decade ago (Eisen-
berg et al., 2001). The bi-functional enzyme UDP-N -acetyl-d-
glucosamine 2-epimerase/N -acetylmannosamine kinase GNE is
the key enzyme of the sialic acid biosynthesis pathway (Hinder-
lich et al., 1997; Stasche et al., 1997). Sialic acid deficiency and
hyposialylation of glycoproteins and glycolipids appear to be a
major underlying defect in GNE myopathy. Consistent with this
hypothesis, a murine disease model for GNE myopathy shows
clinical improvement of muscle strength and function upon
metabolite supplementation of sialic acid or its precursor N -
acetylmannosamine (ManNAc) (Malicdan et al., 2009). Notably
in this context, monomeric sialic acids are decreased in quadriceps
muscle of normal elder males (Marini et al., 2014). Although GNE
myopathy patients can benefit from metabolic precursor supple-
mentation (reviewed by Nishino et al., 2014), it cannot be excluded
that GNE myopathy is caused by additional pathomechanisms
(Krause et al., 2005; Wang et al., 2006; Amsili et al., 2008).
In a GNE myopathy patient myoblast culture model, a primary
defect in response to apoptotic stimuli was observed, in particular
an extended stabilization of pAkt expression (Amsili et al., 2007).
Moreover, in age-related muscle deterioration a critical role for Akt
has also been demonstrated (reviewed by Glass, 2003; Schiaffino
and Mammucari, 2011).
Disturbance of apoptotic signaling was further supported by
proteomic profiling of GNE myopathy muscle biopsy (Sela et al.,
2011). In line with the hypothesis that alterations in mitochon-
drial metabolism might be a primary event in the pathogenetic
cascade of GNE myopathy, mitochondrial deregulation was sug-
gested at the transcriptome and morphological level (Eisenberg
et al., 2008). It is well established that mitochondria are impor-
tant regulators of apoptotic signaling and mitochondrial dysfunc-
tion can contribute to sarcopenia (reviewed in Marzetti et al.,
2012; Marzetti et al., 2013). Although the data sets of individ-
ual proteins regulated in aging skeletal muscle differ substan-
tially between individual proteomic surveys (Gelfi et al., 2006;
Doran et al., 2007; O’Connell et al., 2007, 2008), the main trends
of differentially expressed proteins involved in the cytoskele-
ton architecture, energy metabolism, contraction, cellular sig-
naling and the stress response agree between various studies.
These processes refer to general disturbances in skeletal mus-
cle common to many myopathies and muscular dystrophies.
In search of upstream events more specific to GNE myopa-
thy, previously established transcriptomic data from 10 patients’
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muscle biopsies (Eisenberg et al., 2008; Table S1 in Supplemen-
tary Material) were revisited. Differentially upregulated genes in
GNE myopathy (vs. control samples with p≤ 0.002) were re-
assessed utilizing the DAVID bioinformatics enrichment tool
(Huang da et al., 2009a,b). Interestingly, a significant upregula-
tion of HNRNPA2B1 (1.3-fold; p≤ 0.002) was revealed along with
additional RNA processing and transcription regulators includ-
ing small nuclear ribonucleoprotein polypeptide G (SNRNPG),
arginine/serine-rich-splicing factor 14 (SUGP2/SFRS14), TAR
DNA binding protein (TARDBP), and heterogeneous nuclear
ribonucleoprotein A3 (HNRNPA3). Although the upregulation
of these RNA regulatory factors was comparably small, their
impact on myocellular metabolism might be pathophysiologically
meaningful.
Moreover, Activin A receptor, type II (ACVR2) was among the
most significantly downregulated genes (−0.88-fold; p≤ 0.002)
in GNE myopathy (Eisenberg et al., 2008; Table S1 in Supplemen-
tary Material). Activins are the most efficient negative regulators
of muscle mass (Chen et al., 2014). It remains to be determined
whether reduced ACVR2 expression might represent a compen-
satory mechanism in GNE myopathy to escape or decrease loss of
muscle mass.
Finally, re-evaluation by functional annotation clustering of
downregulated genes in GNE myopathy (Eisenberg et al., 2008)
with the DAVID bioinformatics resources revealed slightly reduced
expression of nuclear or steroid hormone receptors including
hepatocyte nuclear factor 4-gamma (HNF4G), nuclear receptor
subfamily 1, group I, member 3 (NR1I3), and nuclear receptor sub-
family 1, group H, member 2 (NR1H2). Also, vitamin D receptor
(VDR) belongs to the large family of steroid hormone receptors.
Intriguingly, VDR signaling has been implicated in the regulation
of calcium homeostasis, myoblast proliferation, and differentia-
tion and might be a future approach for treatment of sarcopenia
(reviewed in Wagatsuma and Sakuma, 2014). It cannot be excluded
that deregulation of other components of the nuclear or steroid
hormone pathway can contribute to muscle weakness and wasting
in GNE myopathy.
MULTISYSTEM PROTEINOPATHY ASSOCIATED WITH
hnRNPA1 AND hnRNPA2B1 MUTATIONS
Autosomal-dominant mutations in the genes for the heteroge-
neous nuclear ribonucleoproteins HNRNPA1 or HNRNPA2B1 are
rare causes for multisystem proteinopathy (Kim et al., 2013a).
HnRNPA1 and hnRNPA2B1 are multifunctional RNA-binding
proteins involved in the regulation of RNA biogenesis. The clinical
phenotype may present as IBM and may be initially indistinguish-
able from the VCP/p97-related neuromuscular syndromes. The
identified missense mutations are predicted to generate hyper-
stable multimers by their so-called “prion-like” domains (PrLDs),
facilitate recruitment to stress granules, and drive cytoplasmic
aggregate formation (Shorter and Taylor, 2013). Interestingly, also
in sporadic IBM and VCP-associated myopathy, the subcellular
distribution of wild type HNRNPs is altered in skeletal muscle
suggesting disturbances in RNA metabolism (Pinkus et al., 2014)
that might be a secondary event downstream of inflammation or
protein dyshomeostasis. In multisystem proteinopathy, it remains
to be determined whether hnRNPA1 or hnRNPA2B1 mutants
(i) may form immediately cytotoxic oligomers, (ii) overload the
proteolytic capacity of the cell, or (iii) sequester other essential
proteins in cytoplasmic and nuclear aggregates. At the molecu-
lar level, also additional disease mechanisms are conceivable that
may be reminiscent of sarcopenia and relate to age-dependent
alterations in skeletal muscle. A well-established biomarker for
cellular aging is the length of the protective caps at the physical
ends of eukaryotic chromosomes, called telomeres, which shorten
with each cell division cycle and with increasing chronological age.
Telomerase activity is inhibited by large non-coding RNA referred
to as telomeric repeat containing RNA (TERRA), which is tran-
scribed from telomeres. Recent evidence suggests that balanced
levels of hnRNPA1 and TERRA are required to regulate telom-
erase activity (Redon et al., 2013). This finding supports the idea
that hnRNPA1 mutants might also disturb telomere formation
and maintenance thereby contributing to premature aging and
possibly sarcopenia.
Cellular senescence was initially defined as permanent growth
arrest of primary human cells after repeated serial passaging
in vitro (Hayflick and Moorhead, 1961). Cellular senescence is
not only a safeguard against cancer but also of multifunctional
physiological relevance in embryonic development, tissue repair,
and aging. Novel discoveries support the hypothesis that senes-
cence can be a highly dynamic, multi-step process (reviewed
by van Deursen, 2014). Recent evidence demonstrated a close
link between cellular senescence and age-dependent tissue dete-
rioration (Baker et al., 2008). Aging increases CCN1/CYR61
expression leading to muscle senescence (Du et al., 2014).
CCN1/CYR61 depends on exon skipping to provide functional
protein (Hirschfeld et al., 2009). The matricellular protein
CCN1/CYR61 contains several possible binding motifs (YAGR)
in the exon 3–intron 3–exon 4 system for the transcription factor
hnRNPA1. Disturbed or lacking HNRNPA1 due to sequestration
in aggregates as suggested in multisystem proteinopathy might
promote exon 3 inclusion, resulting in non-functional protein
that might compromise muscle angiogenesis and endothelial cell
survival (Leu et al., 2002).
CORRELATION WITH GENETIC SUSCEPTIBILITY OF
SARCOPENIA AND AGE-RELATED GENE EXPRESSION IN
SKELETAL MUSCLE
Hereditary IBM syndromes might involve cellular mechanisms
previously related to sarcopenia and aging. Therefore, several
representative susceptibility genes for sarcopenia (reviewed in
Garatachea and Lucia, 2013) were evaluated to elucidate potential
genetic correlations with hereditary IBMs.
A certain polymorphism in the ACTN3 gene (R577X,
rs1815739) is a well-established marker of a muscular endurance
phenotype in humans. The precise localization of α-actinin 1
and GNE in the myofibrillar apparatus centered on the Z line
remains elusive (Amsili et al., 2008). It is conceivable that phys-
iological interaction by GNE with other resident components
of the sarcomeric Z -disk might modulate cytoskeletal architec-
ture and functions. Interestingly, GNE showed predominant pro-
tein expression in type II fibers in transversal muscle sections
(Krause et al., 2007) and α-actinin 3 is also exclusively detected
in fast-twitch (type II) fibers (Mills et al., 2001).
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The myostatin phenotype is among the most favorable candi-
dates to clarify variance among muscle phenotypes in the elder
population (Garatachea and Lucia, 2013). Accordingly, also the
downregulation of myostatin receptors can modulate myostatin
signaling. As suggested in GNE myopathy, this mechanism could
prevent muscle degeneration and might be considered an adaptive
muscular response.
Epigenetic studies revealed that the differentially methylated
regions related to aging are significantly enriched for muscle
biogenesis (Ong and Holbrook, 2014). Similarly, VCP/p97 can
regulate dynamics and chromatin organization by monoubiquity-
lation of histone H2B (Bonizec et al., 2015) and might contribute
to pathogenic gene expression in IBMPFD.
CONCLUSION
In conclusion, it will be essential to continue studying fundamental
cellular pathways underlying muscular hypertrophy and atrophy
to advance the discovery of promising targets for the development
of causative and safe therapies for skeletal muscle disorders.
An encouraging approach is a novel strategy to promote muscle
maintenance and delay muscular atrophy by utilizing an antibody,
which modulates the activin type II receptor (ActRII) response
(Lach-Trifilieff et al., 2014). The wide therapeutic spectrum holds
promise to treat a variety of progressive neuromuscular conditions
regardless of the underlying molecular defect. Another example of
a non-disease specific treatment option is the molecular chap-
erone 4-phenylbutyrate (4-PBA), an FDA-approved substance to
treat children suffering from urea cycle disorders. 4-PBA acts as
an ER stress inhibitor by aiding in protein folding and preventing
misfolded protein accumulation and aggregation. Recently, con-
vincing evidence was provided that 4-PBA might be also functional
to resolve protein aggregates in vitro and in vivo and to improve
grip strength in a mouse model for plectinopathy, a hereditary
protein aggregate myopathy (Winter et al., 2014).
In summary, recent history of gene identification in heredi-
tary inclusion body myopathies has fostered enthusiasm to facil-
itate detailed understanding of molecular disease mechanisms in
these familial disorders. However, the involved genes show an
unprecedented functional diversity.
Therefore, a plethora of key mechanisms underlying disease
onset in hereditary IBMs remain to be elucidated at the molecu-
lar and physiological level, some of which may be also relevant
for the etiology of sarcopenia. Neglected aspects that may be
specific to the discussed hIBMs include regulation of RNA tran-
scription and processing, cellular senescence, angiogenesis, and
Z -disk architecture.
Understanding the deleterious combination of disease mech-
anisms in detail will be an important goal for future research to
establish targeted intervention strategies and to prevent sarcopenia
in those at risk to develop disease-associated or age-related muscle
loss. Additionally and regardless of the underlying defect, it will be
important for affected patients to immediately translate current
broad understanding of muscle wasting and general advances to
improve muscle function into safe, approved therapy. Clinically,
meaningful improvements for patients suffering from sarcopenia,
hereditary, or degenerative myopathies will be the challenging goal
for the immediate future.
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